Baricitinib (Olumiant▼): risk of venous thromboembolism

This alert advises discontinuation of baricitinib treatment if clinical features of deep vein thrombosis (DVT) or pulmonary embolism (PE) occur. Caution is advised if using baricitinib in patients with risk factors for DVT or PE in addition to rheumatoid arthritis.


Medicines and Healthcare products Regulatory Agency